Essex Investment Management Co. LLC Invests $2.57 Million in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Essex Investment Management Co. LLC acquired a new stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 184,230 shares of the company's stock, valued at approximately $2,566,000. Essex Investment Management Co. LLC owned about 0.21% of Day One Biopharmaceuticals at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Quintet Private Bank Europe S.A. raised its holdings in Day One Biopharmaceuticals by 43.2% in the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company's stock worth $48,000 after acquiring an additional 1,000 shares during the last quarter. SG Americas Securities LLC bought a new position in Day One Biopharmaceuticals during the 2nd quarter valued at about $113,000. Point72 DIFC Ltd bought a new position in Day One Biopharmaceuticals in the 2nd quarter worth about $124,000. Hsbc Holdings PLC bought a new position in Day One Biopharmaceuticals in the 2nd quarter worth about $163,000. Finally, SteelPeak Wealth LLC bought a new position in Day One Biopharmaceuticals in the 2nd quarter worth about $218,000. 87.95% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total transaction of $426,600.00. Following the completion of the transaction, the insider now directly owns 1,097,535 shares in the company, valued at $15,606,947.70. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the business's stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $14.22, for a total transaction of $426,600.00. Following the transaction, the insider now owns 1,097,535 shares of the company's stock, valued at $15,606,947.70. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Jeremy Bender sold 10,681 shares of the business's stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total value of $149,534.00. Following the completion of the sale, the chief executive officer now owns 98,932 shares of the company's stock, valued at $1,385,048. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 68,748 shares of company stock valued at $1,009,272 over the last 90 days. 8.40% of the stock is currently owned by company insiders.

Day One Biopharmaceuticals Trading Up 2.6 %

DAWN stock traded up $0.35 during trading on Friday, reaching $13.88. 1,332,212 shares of the stock were exchanged, compared to its average volume of 923,967. The business has a 50 day moving average price of $13.88 and a 200-day moving average price of $14.41. Day One Biopharmaceuticals, Inc. has a 1 year low of $9.67 and a 1 year high of $18.07. The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of -7.12 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last posted its earnings results on Tuesday, July 30th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.75) by $0.70. The company had revenue of $8.19 million during the quarter, compared to analysts' expectations of $0.90 million. On average, research analysts anticipate that Day One Biopharmaceuticals, Inc. will post -1.68 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on DAWN shares. HC Wainwright reiterated a "buy" rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, August 1st. Piper Sandler restated an "overweight" rating and set a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. Needham & Company LLC raised their price target on shares of Day One Biopharmaceuticals from $32.00 to $33.00 and gave the company a "buy" rating in a research report on Wednesday. Wedbush reiterated an "outperform" rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research report on Thursday, July 25th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 6th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $35.71.

Day One Biopharmaceuticals Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.